Can I stay on a low dose of Wegovy?

5 min read

Written by: 

Grace Gallagher

Reviewed by: 

Austin Ulrich, PharmD, BCACP

Updated:  May 11, 2026

Trusted source badge

Reviewed By

Austin Ulrich, PharmD, BCACP

Austil Ulrich, PharmD, BCACP, is a board-certified ambulatory care pharmacist and freelance medical writer and reviewer. His experience includes direct patient care in hospitals and community pharmacies.

View bio

Key takeaways

  • It’s possible to stay on a low dose of Wegovy (semaglutide) long-term, but that’s not the standard approach. Typically, the medication is increased gradually every few weeks until reaching a maintenance dose.

  • Some people remain on lower doses longer (or indefinitely) because of side effects, access issues, or because they’re already seeing results. Lower doses tend to have fewer side effects, such as nausea and fatigue, but they may also lead to slower weight loss or plateaus.

  • Weight loss is still possible on a low dose, just typically not as much as at higher doses.

Here's what we'll cover

Here's what we'll cover

Key takeaways

  • It’s possible to stay on a low dose of Wegovy (semaglutide) long-term, but that’s not the standard approach. Typically, the medication is increased gradually every few weeks until reaching a maintenance dose.

  • Some people remain on lower doses longer (or indefinitely) because of side effects, access issues, or because they’re already seeing results. Lower doses tend to have fewer side effects, such as nausea and fatigue, but they may also lead to slower weight loss or plateaus.

  • Weight loss is still possible on a low dose, just typically not as much as at higher doses.

If you’ve been prescribed Wegovy (semaglutide), you may know that the medication is not started at its full dose. Instead, Wegovy is designed to be gradually increased until reaching a dose that supports sustained weight loss. Many people wonder: can you stay on a low dose of Wegovy? 

Can I stay on a low dose of Wegovy?

Some people do stay on a low dose of Wegovy long-term, but that’s not the standard approach. When starting Wegovy, a healthcare provider will explain the typical dose-escalation schedule (also called titration), which involves gradually increasing the dose over time (typically to 1.7 mg or 2.4 mg weekly for the injectable form).

This slow ramp-up is thought to reduce side effects. However, some people may decide with their healthcare provider that it makes sense to stay at a lower dose, especially if they’re seeing results or having side effects associated with dose increases.

A lower dose of Wegovy may come with fewer side effects, but also slower weight loss or plateaus. 

One 2025 study comparing titration of semaglutide and tirzepatide found that only about half of participants taking semaglutide reached the recommended maintenance dose, and that this often took longer than expected, at almost five months on average.

This suggests that many people stay on lower doses longer than planned or never increase at all, possibly due to side effects, issues with medication access, or a decision made between a patient and their provider.

Can I stay on a low dose of Wegovy pill? 

Yes, you may choose to stay on a low dose of the Wegovy pill, but this decision should be made alongside a healthcare provider.

Wegovy is available as both an injection and a pill. Oral semaglutide typically follows a 90-day titration schedule with dose increases every 30 days. Most people start with a once-daily 1.5 mg dose and increase every 30 days until they reach 25 mg — with four dose steps along the way: 1.5 mg, 4 mg, 9 mg, and 25 mg.

That said, not everyone follows that path all the way up. Some people may stay at a lower dose of the Wegovy pill because they’re seeing steady progress or are experiencing intolerable side effects with each step up.

It’s also worth noting that the Wegovy pill appears to produce slightly less weight loss than the injection, even at the full dose. In clinical studies, people taking 25 mg of oral Wegovy lost about 13.6% of their starting body weight over 64 weeks, compared with about 14.9% over 68 weeks with the injectable form.

Reasons for staying on a low dose of Wegovy 

There are a few reasons why someone may be interested in staying on a low dose of Wegovy.

  • Fewer side effects: Lower doses of semaglutide tend to be easier to tolerate. At a lower dose, people may experience fewer Wegovy side effects, including reduced nausea, fatigue, headache, or constipation, which can make long-term use more sustainable.

  • Gradual weight loss: Research shows semaglutide produces a dose-dependent effect. In clinical trials, average weight loss ranged from about 3%–4% of starting body weight in people with diabetes at lower doses (0.5 mg to 1 mg), with higher doses (2.4 mg) producing up to 15% average weight loss over time.

  • Reaching your goal: Some people may reach their goal weight before titrating up to the highest Wegovy dose, in which case staying at a lower dose of Wegovy may be a reasonable option.

  • Maintenance: Research suggests that many people who discontinue semaglutide altogether will regain a significant portion of the weight lost within a few years. For this reason, continuing treatment with a dose that works — even a lower dose — can help prevent weight regain.

  • Individual response: Clinical studies can offer insight into the average response to medications like Wegovy, but results vary widely from person to person. Some people respond strongly to a lower dose of Wegovy, while others need higher doses to reach their desired weight loss goals.

Can you lose weight on a low dose of Wegovy?

Yes, weight loss is possible on a low dose of Wegovy, but typically to a lesser extent than with higher doses. This is why most semaglutide treatment plans involve gradual dose increases. Semaglutide shows a dose-dependent effect, meaning greater weight loss tends to occur at higher doses.

One 2023 study looked at 1,606 adults taking oral semaglutide — who were on average 58 years old — and found that over the course of a year:

  • People taking 14 mg daily lost about 10 pounds on average.

  • People taking 25 mg daily lost about 14.8 pounds.

  • People taking 50 mg daily lost about 17.5 pounds.

The trial also found that higher doses of semaglutide led to greater weight loss and greater improvements in blood sugar levels. Keep in mind though, that this study only included people who had type 2 diabetes, and the maximum approved dose of oral Wegovy is 25 mg daily.

Wegovy dosing schedule and basics 

Wegovy is available as both a daily pill and a weekly injection, and each form has its own dosing schedule and strengths.

The Wegovy pill is taken once daily and comes in four strengths: 1.5 mg, 4 mg, 9 mg, and 25 mg. Each bottle contains 30 tablets. Typically, doses increase every 30 days until reaching 25 mg at around 91 days. If side effects become a concern, a healthcare provider may slow the titration schedule.

The Wegovy injection is taken once weekly and comes in six strengths: 0.25 mg, 0.5 mg, 1 mg, 1.7 mg, 2.4 mg, and 7.2 mg. While the standard maintenance dose is 2.4 mg weekly, some people (with guidance from their provider) may choose to remain at 1.7 mg if it’s better tolerated. And some may increase to the 7.2 mg dose if more weight loss is needed. Each carton includes four pens (one per week), with dose increases typically happening every four weeks until around the 17-week mark. If increasing to the maximum 7.2 mg weekly dose, it would take another 4 weeks to reach that dose.

What affects Wegovy dosing

Wegovy dosing largely depends on how well the medication is tolerated and the individual’s weight loss progress. 

  • Side effects: It’s common practice for a healthcare provider to check in on how an individual is tolerating the current dose before increasing it. If side effects feel manageable, the dose is usually increased as planned. If they’re significantly affecting quality of life, the healthcare provider may recommend staying on the current dose longer or, in some cases, stepping back to a lower dose.

  • Individual response: Everyone responds differently to semaglutide. Some people will experience side effects, while others do not. Some may reach their goal weight at a lower dose and not need to titrate up. It’s also worth noting that at very high doses, appetite suppression can become excessive — a factor worth discussing with a healthcare provider. 

It’s important to follow the titration schedule set out by a healthcare provider. Starting at a high Wegovy dose doesn’t usually allow the body enough time to adjust to the medication.

Low dose of Wegovy side effects 

Any dose of semaglutide can cause side effects, although they are likely less pronounced on a low dose. Some people also notice that their side effects temporarily increase with each dose increase. 

Wegovy side effects at a low dose include:

  • Digestive changes (diarrhea or constipation):  Some people experience changes in bowel habits as the digestive system adjusts, though symptoms are usually temporary at low doses. Constipation and diarrhea are both possible side effects, though diarrhea may be more common.

  • Bloating or mild stomach discomfort: Wegovy slows gastric emptying (the rate at which food leaves the stomach), which can cause bloating and mild stomach discomfort.

  • Fatigue: Some people report feeling more tired in the early stages of treatment, potentially due to reduced calorie intake or dehydration.

  • Headache or dizziness: Headaches are a common side effect of Wegovy, reported in up to 17% of people in clinical trials. This may be triggered by dehydration or low blood sugar if people are not eating enough.

Bottom line

Wegovy is designed to be increased from a low dose to a higher maintenance dose. However, some people choose to stay on a lower dose indefinitely, and that can be a reasonable option for some.

  • For people experiencing significant side effects, a lower dose of Wegovy may be easier to tolerate long-term.

  • A low dose can still support weight loss and help maintain results, even if progress is slower.

  • The “right” dose isn’t always the highest one — it’s the one that works sustainably for a given individual, under medical guidance.

Frequently asked questions (FAQs)

DISCLAIMER

If you have any medical questions or concerns, please talk to your healthcare provider. The articles on Health Guide are underpinned by peer-reviewed research and information drawn from medical societies and governmental agencies. However, they are not a substitute for professional medical advice, diagnosis, or treatment.

Wegovy Important Safety Information: Read more about serious warnings and safety info.

References

  • Alvarez, G., Veliz, L., Michaels, S., et al. (2025). Evaluating dose titration in semaglutide and tirzepatide for weight loss: A retrospective academic call center study. Obesities, 5(4), 90. https://doi.org/10.3390/obesities5040090. Retrieved from https://www.mdpi.com/2673-4168/5/4/90

  • Aroda, V. R., Aberle, J., Bardtrum, L., et al. (2023). Efficacy and safety of once-daily oral semaglutide 25 mg and 50 mg compared with 14 mg in adults with type 2 diabetes (PIONEER PLUS): A multicentre, randomised, phase 3b trial. The Lancet, 402(10403), 693–704. Retrieved from https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(23)01127-3/abstract

  • Canadian Agency for Drugs and Technologies in Health. (2025). Semaglutide (Wegovy): Therapeutic area: Weight management: Reimbursement review. NCBI Bookshelf. Retrieved from https://www.ncbi.nlm.nih.gov/books/NBK619926/

  • Cengiz, A., Wu, C. C., & Lawley, S. D. (2025). Alternative dosing regimens of GLP‐1 receptor agonists may reduce costs and maintain weight loss efficacy. Diabetes, Obesity And Metabolism, 27(4), 2251–2258. doi: 10.1111/dom.16229. Retrieved from https://pmc.ncbi.nlm.nih.gov/articles/PMC11885104/

  • Gao, X., Hua, X., Wang, X., et al. (2022). Efficacy and safety of semaglutide on weight loss in obese or overweight patients without diabetes: A systematic review and meta-analysis of randomized controlled trials. Frontiers In Pharmacology, 13, 935823. doi: 10.3389/fphar.2022.935823. Retrieved from https://pmc.ncbi.nlm.nih.gov/articles/PMC9515581/

  • Gentinetta, S., Sottotetti, F., Manuelli, M., & Cena, H. (2024). Dietary Recommendations for the Management of Gastrointestinal Symptoms in Patients Treated with GLP-1 Receptor Agonist. Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy, 17, 4817–4824. doi: 10.2147/DMSO.S494919. Retrieved from: https://pmc.ncbi.nlm.nih.gov/articles/PMC11668918/

  • Ghusn, W., De la Rosa, A., Sacoto, D., et al. (2022). Weight loss outcomes associated with semaglutide treatment for patients with overweight or obesity. JAMA Network Open, 5(9), e2231982. doi: 10.1001/jamanetworkopen.2022.31982. Retrieved from https://pmc.ncbi.nlm.nih.gov/articles/PMC9486455/

  • Kommu, S. & Whitfield, P. (2024). Semaglutide. StatPearls. Retrieved from https://www.ncbi.nlm.nih.gov/sites/books/NBK603723/

  • Sorli, C., Harashima, S., Tsoukas, G. M., et al. (2017). Efficacy and safety of once-weekly semaglutide monotherapy versus placebo in patients with type 2 diabetes (SUSTAIN 1): A double-blind, randomised, placebo-controlled, parallel-group, multinational, multicentre phase 3a trial. The Lancet Diabetes & Endocrinology, 5(4), 251–260. doi: 10.1016/S2213-8587(17)30013-X. Retrieved from https://pubmed.ncbi.nlm.nih.gov/28110911/

  • U.S. Food and Drug Administration (FDA). (2026). Prescribing information: Wegovy (semaglutide) injection and tablets. Retrieved from https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/215256s029lbl.pdf

  • Wharton, S., Lingvay, I., Bogdanski, P., et al. (2025). Oral semaglutide at a dose of 25 mg in adults with overweight or obesity. The New England Journal Of Medicine, 393(11), 1077–1087. doi: 10.1056/NEJMoa2500969. Retrieved from https://www.nejm.org/doi/10.1056/NEJMoa2500969

  • Wilding, J. P. H., Batterham, R. L., Calanna, S., et al. (2021). Once-Weekly Semaglutide in Adults with Overweight or Obesity. The New England Journal of Medicine, 384(11), 989–1002. doi: 10.1056/NEJMoa2032183. Retrieved from https://www.nejm.org/doi/full/10.1056/NEJMoa2032183

  • Wilding, J. P. H., Batterham, R. L., Davies, M., et al. (2022). Weight regain and cardiometabolic effects after withdrawal of semaglutide: The STEP 1 trial extension. Diabetes, Obesity And Metabolism, 24(8), 1553–1564. doi: 10.1111/dom.14725. Retrieved from https://pmc.ncbi.nlm.nih.gov/articles/PMC9542252/

What’s included

Provider consultation

GLP-1 prescription (if appropriate)

Insurance coverage & paperwork handled

Ongoing care & support

Tools to track progress

Please note: The cost of medication is not included in the Ro Body membership.